Pharma BD Deal Intelligence
A validated bet so far: Avenzo paid up to $50M near-term on VelaVigo's Nectin-4/TROP2 bispecific ADC, then exercised its option in September 2025 alongside FDA IND clearance and landed Fast Track designation in November 2025 — though the $750M in later milestones remain unearned.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Avenzo Therapeutics provides corporate update and announces closing of $150 million Series A/A-1 financing to advance its clinical-stage oncology pipeline. The…
VelaVigo secures an exclusive licensing option for a Nectin4/TROP2 bispecific antibody-drug conjugate with Avenzo Therapeutics. The bispecific ADC targets two…
FDA granted Fast Track designation to AVZO-103 for adult patients with locally advanced or metastatic urothelial cancer previously treated with enfortumab…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Avenzo Therapeutics entered an exclusive option agreement with VelaVigo (Nov 25, 2024) for global (ex-Greater China) rights to a first-in-class Nectin-4/TROP2 bispecific ADC (AVZO-103, formerly VAC-103). Terms: upfront plus near-term option-exercise milestones up to $50M and up to $750M in development/regulatory/commercial milestones plus tiered royalties. On Sept 2, 2025 Avenzo announced it had EXERCISED its exclusive option from VelaVigo - securing global ex-Greater China development, manufacturing and commercialization rights - concurrent with FDA clearance of the AVZO-103 IND. Avenzo initiated the BEACON-1 Phase 1/2 first-in-human study (NCT07193511; 355 patients planned) on Oct 2, 2025 in locally advanced or metastatic urothelial cancer and other solid tumors. On Nov 24, 2025 the FDA granted AVZO-103 Fast Track designation for la/mUC previously treated with enfortumab vedotin (Padcev), a population with no approved ADCs.
18K US cases/yr · $2.6B 7 major markets urothelial carcinoma therapy market 2024 (IMARC Group) · 750 Total VelaVigo back-end biobucks (USD MM, dev/reg/commercial milestones)
Urothelial carcinoma (UC), predominantly originating in the bladder, is the sixth most common cancer in the US with an estimated 83,190 new cases and 16,840 deaths in 2024 per American Cancer Society. Roughly 5-10% of patients present with metastatic disease at diagnosis, and approximately 30% of muscle-invasive cases progress to metastatic disease, translating to ~15,000-20,000 US patients per year with advanced/metastatic urothelial carcinoma (la/mUC). First-line standard of care was reset in December 2023 when the FDA approved enfortumab vedotin (Padcev, Astellas/Pfizer) plus pembrolizumab (Keytruda, Merck) for la/mUC based on EV-302, which demonstrated median overall survival of 31.5 months versus 16.1 months for platinum chemotherapy - effectively doubling survival. Nectin-4, the target of enfortumab vedotin, is a cell-adhesion molecule highly expressed in bladder cancer and several other solid tumors including breast, ovarian, and non-small cell lung cancer. TROP2 is similarly overexpressed across urothelial, breast, and lung carcinomas and is the target of sacituzumab govitecan (Trodelvy) and datopotamab deruxtecan (Datroway). Because Nectin-4 and TROP2 are frequently co-expressed in urothelial and other tumors, a bispecific ADC that engages both antigens could provide deeper tumor payload delivery, overcome single-target heterogeneity-driven resistance, and extend benefit beyond current Padcev and Trodelvy monotherapy.
The urothelial carcinoma ADC landscape is defined by Nectin-4 and TROP2 franchises, with bispecific ADCs as the next-generation layer. Nectin-4 monotherapies: enfortumab vedotin (Padcev, Astellas/Pfizer - now 1L backbone with pembrolizumab post-EV-302), plus emerging Nectin-4 ADCs from Daiichi Sankyo/Merck and various Chinese biotechs. TROP2 ADCs: sacituzumab govitecan (Trodelvy, Gilead - approved la/mUC second-line), datopotamab deruxtecan (Datroway, Daiichi Sankyo/AstraZeneca - lung cancer approved, breast/UC pipeline), sacituzumab tirumotecan (Sac-TMT, Kelun-Biotech/Merck). Checkpoint inhibitor backbone: pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS - adjuvant), avelumab (Bavencio, Merck KGaA/Pfizer - maintenance), durvalumab (Imfinzi, AstraZeneca). FGFR-targeted: erdafitinib (Balversa, Janssen - FGFR3/2 altered). Nectin-4 x TROP2 bispecific ADCs (the VelaVigo thesis): VBS-001/AVZO-103 (VelaVigo/Avenzo - global ex-China license), plus pipeline bispecifics from Duality Biologics, Hansoh, and others. The Avenzo option exercise was triggered in 2025 with AVZO-103 IND cleared, validating the bispecific-ADC class.
VelaVigo grants Avenzo an exclusive option to license the Nectin-4/TROP2 bispecific ADC globally ex-Greater China; up to $50M near-term + up to $750M milestones plus royalties.
Avenzo exercised its exclusive option, securing global ex-Greater China development, manufacturing and commercialization rights to AVZO-103, concurrent with FDA IND clearance.
FDA cleared the IND for AVZO-103 (formerly VAC-103), the Nectin4/TROP2 bispecific ADC.
First-in-human Phase 1/2 study of AVZO-103 begins in la/mUC and other solid tumors; 355 patients planned; recruiting.
Fast Track designation granted for la/mUC previously treated with enfortumab vedotin.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Avenzo Therapeutics Inc. / VelaVigo Bio Inc. (this deal) | 2024 | $800M | — |
| Avenzo Therapeutics Inc. / Duality Biotherapeutics, Inc. | 2025 | $1.2B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2024 deals · Oncology deals